Guangqiang Jiang - Axonics Modulation Chief Officer
Executive
Dr. Guangqiang Jiang, Ph.D. is the Chief Technology Officer of the Company. From October 2000 to October 2013, Mr. Jiang served as Vice President, Director of Research and Development, Director of Engineering and Engineering Manager of AMF, a nonprofit medical research corporation and the current licensor of our rSNM System since 2015.
| Age | 50 |
| Tenure | 10 years |
| Phone | 949 396 6322 |
| Web | https://www.axonics.com |
Axonics Modulation Management Efficiency
Axonics Modulation's management efficiency ratios could be used to measure how well Axonics Modulation manages its routine affairs as well as how well it operates its assets and liabilities.Axonics Modulation Technologies currently holds 27.62 M in liabilities with Debt to Equity (D/E) ratio of 0.02, which may suggest the company is not taking enough advantage from borrowing. Axonics Modulation has a current ratio of 10.28, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Axonics Modulation's use of debt, we should always consider it together with its cash and equity.
Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Deanna Wilke | LivaNova PLC | N/A | |
| Dan Yarbrough | Orthofix Medical | N/A | |
| MPH MD | Medtronic PLC | N/A | |
| Andres Cedron | Orthofix Medical | 44 | |
| Michael McBreen | Integra LifeSciences Holdings | 59 | |
| Olaf Hedrich | Medtronic PLC | N/A | |
| Matt Walter | Medtronic PLC | N/A | |
| Chris Calcaterra | Glaukos Corp | 65 | |
| Mervin Smith | iRhythm Technologies | 49 | |
| Kelley Nicholas | Neuropace | N/A | |
| Dylan John | Neuropace | N/A | |
| Ruth Fleming | Integra LifeSciences Holdings | N/A | |
| Ahmet Tezel | LivaNova PLC | N/A | |
| Lucas Vitale | Orthofix Medical | 47 | |
| Joel Batts | Orthopediatrics Corp | N/A | |
| Mark Jesser | Integra LifeSciences Holdings | N/A | |
| Jane Rady | Glaukos Corp | 76 | |
| John Harris | Integer Holdings Corp | 65 | |
| Hollie Foust | CONMED | N/A | |
| Chad Patterson | iRhythm Technologies | 42 | |
| Guy Yoskovitz | Nano X Imaging | 45 | |
Management Performance
| Return On Equity | -0.0089 | |||
| Return On Asset | -0.0063 |
Axonics Modulation Leadership Team
Elected by the shareholders, the Axonics Modulation's board of directors comprises two types of representatives: Axonics Modulation inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Axonics. The board's role is to monitor Axonics Modulation's management team and ensure that shareholders' interests are well served. Axonics Modulation's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Axonics Modulation's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Alfred Ford, Chief Commercial Officer | ||
| Danny Dearen, Chief Operating and Financial Officer | ||
| MD MAS, Chief Officer | ||
| Raymond Cohen, CEO, Director | ||
| Rinda Sama, Chief Officer | ||
| JD Esq, General VP | ||
| Aaron Pettit, General Officer | ||
| Kari Keese, Chief Officer | ||
| John Woock, Chief Marketing Officer | ||
| Neil Bhalodkar, Vice Relations | ||
| Guangqiang Jiang, Chief Officer |
Axonics Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Axonics Modulation a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.0089 | |||
| Return On Asset | -0.0063 | |||
| Profit Margin | (0.01) % | |||
| Operating Margin | (0.02) % | |||
| Current Valuation | 3.32 B | |||
| Shares Outstanding | 51.11 M | |||
| Shares Owned By Insiders | 1.26 % | |||
| Shares Owned By Institutions | 87.22 % | |||
| Number Of Shares Shorted | 3.31 M | |||
| Price To Earning | (10.68) X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. You can also try the Portfolio Manager module to state of the art Portfolio Manager to monitor and improve performance of your invested capital.
Other Consideration for investing in Axonics Stock
If you are still planning to invest in Axonics Modulation check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Axonics Modulation's history and understand the potential risks before investing.
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume |